Thursday, 25 April 2024 07:28 AM
July 25, 2018 00:05 am
U.S. regulators have approved a simple, one-dose treatment to prevent relapses of Plasmodium vivax malaria. One dose of GlaxoSmithKline’s Krintafel (tafenoquine) prevented relapses in three-in-four patients.